Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Bardia, Aditya; A. Hurvitz, Sara; M. Tolaney, Sara; Loirat, Delphine; Punie, Kevin; Oliveira, Mafalda; Brufsky, Adam; Sardesai, Sagar; Kalinsky, Kevin; Zelnak, Amelia; Weaver, Robert; A. Traina, Tiffany; Dalenc, Florence; Aftimos, Philippe; Lynce, Filipa; Diab, Sami; Cortés, Javier; O’Shaughnessy, Joyce; Dièras, Véronique; Ferrario, Cristiano; Schmid, Peter; A. Carey, Lisa; Gianni, Luca; Piccart, Martine; Loibl, Sibylle; M. Goldenberg, David; Hong, Quan; Olivo, Martin; M. Itri, Loretta; S. Rugo, Hope

doi:10.1056/nejmoa2028485

Public

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Published in New England Journal of Medicine • Apr 21, 2021

Authors:

Aditya Bardia

Sara A. Hurvitz

Sara M. Tolaney

Abstract

BACKGROUND: Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-3...

Subject

Medicine

Internal medicine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!